Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications primarily used to treat type 2 diabetes. GLP-1s work by regulating the production of insulin and lowering your blood sugar.

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

For the first time in decades, the prevalence of obesity has not increased in the USA, according to the latest National Health and Nutrition Examination Survey from the US Centers for Disease Control ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...

Pendulum Therapeutics latest innovation comes in the form of a GLP-1 probiotic, acting as an appetite suppressor and healthy ...

But the use of GLP-1 agonists has changed how people and their health care providers approach weight management. In this webinar, you’ll learn about GLP-1 agonists that can help with obesity ...

The backdrop: The Lin paper has come out as analysts are starting to try to compare the economic benefits of GLP-1 agonists to the cost of the drugs. Analysts at Moody's have suggested that ...

Data reported earlier Monday from Viking Therapeutics (NASDAQ:VKTX) on its weight loss medicine VK2735 indicates that Novo ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

Evoke Pharma reports positive results for a study on GIMOTI. Evoke Pharma stock has now tripled since early September.